NEW YORK, Oct. 3, 2024 /PRNewswire/ -- Report on how AI is driving market transformation- The global enzyme-linked immunosorbent assay (elisa) market  size is estimated to grow by USD 843.9 million from 2024-2028, according to Technavio. The market is estimated to grow at a CAGR of about 16.82%  during the forecast period. Growing need for frequent diagnostic testing among aging population is driving market growth, with a trend towards growing importance of promotional activities. However, lack of accessibility and affordability of diagnostic tests in developing countries  poses a challenge. Key market players include Abbott Laboratories, Abcam plc, Agilent Technologies Inc., Amgen Inc., Avantor Inc., Becton Dickinson and Co., Bio Rad Laboratories Inc., bioMerieux SA, Cardinal Health Inc., Crux Biolabs Pty Ltd., Danaher Corp., Eppendorf SE, Illumina Inc., Lonza Group Ltd., Merck KGaA, Novo Nordisk AS, Perkin Elmer Inc., QIAGEN NV, Siemens Healthineers AG, and Thermo Fisher Scientific Inc..

AI-Powered Market Evolution Insights. Our comprehensive market report ready with the latest trends, growth opportunities, and strategic analysis- View your snapshot now

Key Market Trends Fueling Growth

The Enzyme-Linked Immunosorbent Assay (ELISA) market presents unique challenges for vendors due to its specialized nature and niche end-user base. Brand and product visibility play a limited role in sales, as technical expertise and distribution networks are prioritized. ELISA testing's intricacies necessitate extensive support materials for end-users. Thermo Fisher Scientific provides such resources through PDF documents, brochures, and YouTube videos. Bio-Rad Laboratories also utilizes YouTube for detailed explanations. European research organizations collaborate with pharma companies to conduct annual workshops, promoting ELISA tests for disease detection. Vendors are recognizing the importance of promotional activities as product enhancements emerge, signaling market growth during the forecast period. 

The Enzyme-Linked Immunosorbent Assay (ELISA) market is experiencing significant growth due to its wide application in various industries. Key trends include environmental monitoring, food testing, and clinical diagnostics. The aging population and increasing screening programs drive the demand for ELISA in clinical diagnostics. Next-generation sequencing and assay development enhance ELISA's sensitivity, specificity, and reduce cross reactivity. ELISA plays a crucial role in drug discovery, food safety testing, and biotechnology. Peptides, cytokines, and soluble proteins are common target substances for ELISA. ELISA's ability to measure concentration and its use in pregnancy tests, serosurveillance, and immunology makes it an essential diagnostic tool. Public health emergencies, such as HIV or AIDS, hepatitis, Lyme disease, and dengue fever, are diagnosed using ELISA tests. ELISA's versatility is evident in its use as diagnostic tools for infectious diseases, clinical diagnostic devices, and vaccine development. WHO data highlights the importance of ELISA in various applications, including direct, indirect, sandwich, and competitive ELISA. 

Insights on how AI is driving innovation, efficiency, and market growth- Request Sample!

• The Enzyme-Linked Immunosorbent Assay (ELISA) market faces significant challenges, particularly in developing countries. High-quality diagnostic tests are essential for effective disease management and the development of new therapies. However, these tests are often inaccessible and unaffordable in countries with a high disease burden. Pricing is a major issue for vendors in countries like India and China due to the absence of widespread insurance programs. International initiatives providing affordable diagnostics are limited to specific disease-control programs and are not sustainable in the long term. These challenges hinder the growth of the global ELISA market and have far-reaching consequences for the overall health and well-being of the populations in these countries. Technology transfer and local production could be potential solutions, but their implementation faces numerous obstacles.
  
  
• The Enzyme-Linked Immunosorbent Assay (ELISA) market is witnessing significant growth due to the increasing demand for diagnostic tools in the healthcare industry. Infectious diseases such as HIV or AIDS, hepatitis, Lyme disease, and dengue fever drive the need for ELISA tests in diagnosis. According to WHO data, ELISA is the most common diagnostic method for HIV and hepatitis. ELISA formats like Direct, Indirect, Sandwich, and Competitive are used for various applications including vaccine development, immunology, toxicology, drug monitoring, transplantation, and cancer. ELISA is also used for protein quantitation in industries like pharmaceuticals, hospitals, and research laboratories. Challenges such as chronic diseases, autoimmune disorders, diabetes, prediabetes, and multidisciplinary assays are being addressed through advanced ELISA formats like chemiluminescent, colorimetric, and fluorescent. ELISA instruments and software solutions offer faster turnaround times, making them preferred choices over alternatives like PCR and next-generation sequencing in certain applications. The ELISA market is expected to continue growing due to its versatility and wide range of applications.

Insights into how AI is reshaping industries and driving growth- Download a Sample Report

Segment Overview 

This enzyme-linked immunosorbent assay (elisa) market report extensively covers market segmentation by

1. Application 
• 1.1 Vaccine development
• 1.2 Immunology
• 1.3 Diagnostics
• 1.4 Drug monitoring and pharmaceutical industry
• 1.5 Others
2. End-user 
• 2.1 Hospitals and diagnostic centers
• 2.2 Research laboratories
• 2.3 Others
3. Geography 
• 3.1 North America
• 3.2 Europe
• 3.3 Asia
• 3.4 Rest of World (ROW)

1.1 Vaccine development-  The Enzyme-Linked Immunosorbent Assay (Elisa) market plays a significant role in the vaccine development process. Elisa is a widely used technique for measuring antibodies in biological fluids or culture media. In vaccine development, Elisa is employed to determine the immune response towards a vaccine candidate during the preclinical stages. This assay technique forms an immune complex between the antibody and antigen. The vaccine development process is lengthy and complex, involving several stages. After identifying antigens in the exploratory stage, immunogenicity and safety are assessed using animal models and preclinical cell cultures. Following approval of an Investigational New Drug application, clinical trials ensue. Elisa assays are developed and validated during the preclinical and early clinical trial phases, ensuring they meet stringent parameters and criteria before lot release. Elisa's role in vaccine development is crucial, as it helps analyze the efficacy of the vaccine candidate. These assays are often paired with inhibition assays to study the immune response to the growth of the pathogen. Continuous research and development efforts are being made to improve Elisa, driving the growth of the Elisa testing market in the vaccine development segment during the forecast period.

Download complimentary Sample Report to gain insights into AI's impact on market dynamics, emerging trends, and future opportunities- including forecast (2024-2028) and historic data (2018 - 2022) 

The Enzyme-Linked Immunosorbent Assay (ELISA) market is witnessing significant growth due to the increasing prevalence of infectious diseases such as HIV or AIDS, hepatitis, Lyme disease, and others. According to WHO data, infectious diseases continue to be a major global health threat, driving the demand for reliable diagnostic tools like ELISA tests. ELISA is a versatile diagnostic technique used for detecting proteins, antibodies, and hormones in various samples. It comes in different formats, including Direct ELISA and Indirect ELISA, and is used in medical diagnostics, pharmaceutical industries, environmental monitoring, food testing, and clinical diagnostics. The regulatory framework for ELISA is well-established, ensuring the production of accurate and reliable results. ELISA formats like Multiplex ELISA offer the advantage of testing multiple analytes in a single run, reducing turnaround times. The aging population and the increasing awareness of early disease detection are further fueling the growth of the ELISA market. Instruments and software solutions are also an integral part of the ELISA ecosystem, ensuring standardization and efficiency in the diagnostic process.

Market Research Overview

The Enzyme-Linked Immunosorbent Assay (ELISA) market is a significant segment of the medical diagnostics industry, with applications in various fields including infectious diseases, immunology, toxicology, drug monitoring, transplantation, cancer research, protein quantitation, and more. ELISA tests play a crucial role in the diagnosis of diseases such as HIV or AIDS, hepatitis, Lyme disease, and dengue fever, among others. WHO data indicates that ELISA tests are used in over 70% of all diagnostic tests for infectious diseases. ELISA formats include Direct ELISA, Indirect ELISA, Sandwich ELISA, Competitive ELISA, and others. ELISA is also used in vaccine development, drug discovery, food safety testing, environmental monitoring, and personalized medicine. ELISA instruments and software solutions offer turnaround times that are faster than conventional methods like PCR and Next-Generation Sequencing. ELISA is used to measure the concentration of target substances such as proteins, antibodies, hormones, peptides, and cytokines. ELISA assays are used in hospitals, research laboratories, and clinical diagnostics. The aging population and screening programs have led to an increased demand for ELISA tests for chronic diseases and autoimmune disorders like diabetes and prediabetes. ELISA assays offer high sensitivity, specificity, and low cross reactivity, making them a preferred choice for diagnostic applications. ELISA formats include chemiluminescent, colorimetric, and fluorescent, each with its advantages. ELISA is used in various industries, including pharmaceuticals, biotechnology, and clinical diagnostic devices.

1 Executive Summary
2 Market Landscape
3 Market Sizing
4 Historic Market Size
5 Five Forces Analysis
6 Market Segmentation

• Application
• Vaccine Development
• Immunology
• Diagnostics
• Drug Monitoring And Pharmaceutical Industry
• Others
• End-user
• Hospitals And Diagnostic Centers
• Research Laboratories
• Others
• Geography
• North America
• Europe
• Asia
• Rest Of World (ROW)

7 Customer Landscape
8 Geographic Landscape
9 Drivers, Challenges, and Trends
10 Company Landscape
11 Company Analysis
12 Appendix

Technavio is a leading global technology research and advisory company. Their research and analysis focuses on emerging market trends and provides actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions.

With over 500 specialized analysts, Technavio's report library consists of more than 17,000 reports and counting, covering 800 technologies, spanning across 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavio's comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios.

Technavio Research
Jesse Maida
Media & Marketing Executive
US: +1 844 364 1100
UK: +44 203 893 3200
Email: media@technavio.com
Website: www.technavio.com/

View original content to download multimedia:https://www.prnewswire.com/news-releases/enzyme-linked-immunosorbent-assay-elisa-market-to-grow-by-usd-843-9-million-2024-2028-as-ai-drives-demand-for-frequent-diagnostic-testing-302265146.html

SOURCE Technavio